![](https://i0.wp.com/shacklemedia.com/wp-content/uploads/2023/11/abbvie-to-buy-immunogen-for-more-than-10-billion.jpg?w=640&ssl=1)
Nov. 30, 2023 7:51 am ET
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.
AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price of $16.06 for the Waltham, Mass., pharmaceutical company.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Source: finance.yahoo.com
Related posts:
California insurance market rattled by withdrawal of major companies
1 No Brainer Warren Buffett Dividend Stock to Buy in 2024 and Hold Forever
Stock market news live updates: Stocks tank after higher-than-expected CPI report
Microsoft Kicked Off 2024 by Announcing One of Its Biggest Changes in Over 30 Years. Here's What It ...
Xi Jinping's visit to Saudi Arabia is bad news for the Kremlin